Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. SyntheticMR AB (publ)
  6. News
  7. Summary
    SYNT   SE0015987946

SYNTHETICMR AB (PUBL)

(SYNT)
  Report
End-of-day quote NORDIC GROWTH MARKET  -  2023-06-06
27.90 SEK   +2.20%
05/31SyntheticMR Receives Regulatory Approval for their Innovative SyMRI Software Solution in South Korea
AQ
05/31SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea
CI
05/24Report from Annual General Meeting in SyntheticMR AB (publ)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nemours Children's Health to Implement SyntheticMR's product SyMRI in Clinical Practice

02/14/2022 | 10:55am EDT

Nemours Children's Health will be integrating SyntheticMR's product SyMRI NEURO at their hospital in Orlando, Florida, to improve scan speed, provide myelin mapping and increase overall clinical efficiency.

Nemours Children's Health is a leader in pediatric care as well as research and clinical trials. Their goal is to prevent and reverse childhood diseases, improve healthcare delivery and keep children safe and healthy for many generations to come. To help answer some of the most pressing questions in children's health, Nemours' Dr. Laura Hayes, will be integrating the SyMRI software into her daily practice. Dr. Hayes is board certified in Diagnostic Radiology and Pediatric Radiology, with additional fellowship training in Pediatric Neuroradiology.

In clinical practice, Dr. Hayes is looking forward to utilizing SyMRI's speed efficiency and myelin mapping. Speed is of major importance in the pediatric field to avoid sedation and ensure that scans can be done quickly, but effectively. Additionally, myelin mapping will be a significant tool as it provides pediatric reference curves to help determine normal myelination, hypo-myelination and more. These reference curves aid the assessment and help save reading time.

"Having a reference for what's normal at this age is key because there is rapid brain development and myelin changes over the early years. You must know what's normal for age and what's not. Baby brains are the hardest scans to read so we need all the tools we can get to help with those," says Dr. Hayes.

SyntheticMR looks forward to providing Dr. Hayes and Nemours Children's with tools to support a more precise diagnosis, reliable monitoring and personalized treatment strategies for her pediatric patients, and to be part of improving pediatric patient care worldwide.

"Having the opportunity to partner with such a well-known pediatric center like Nemours Children's Hospital, Florida really shows the value that SyMRI can bring to those patients that truly need and deserve the best-in-class care.  We believe in the care that Nemours provides and are honored to be part of their mission of restoring and improving the health of children through care and programs not readily available," says Kyle Frye, President Americas & ANZ and CCO of SyntheticMR.

For additional information, please contact Kyle Frye, President Americas & ANZ and CCO at SyntheticMR +1 (859) 512-9496 kyle.frye@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI KNEE and SyMRI SPINE provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI KNEE and SyMRI SPINE is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.

https://news.cision.com/syntheticmr-ab/r/nemours-children-s-health-to-implement-syntheticmr-s-product-symri-in-clinical-practice,c3506372

https://mb.cision.com/Main/11663/3506372/1534841.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about SYNTHETICMR AB (PUBL)
05/31SyntheticMR Receives Regulatory Approval for their Innovative SyMRI Software Solution i..
AQ
05/31SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution i..
CI
05/24Report from Annual General Meeting in SyntheticMR AB (publ)
AQ
05/23Interim report January - March 2023
AQ
05/23SyntheticMR AB Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
04/14Notice to attend the annual general meeting of SyntheticMR AB (publ)
AQ
04/11SyntheticMR publishes annual report for 2022
AQ
03/24Syntheticmr : Receives regulatory approval for SyMRI in Singapore
PU
03/24SyntheticMR's Innovative SyMRI Software Receives Regulatory Approval in Singapore
AQ
03/02SyntheticMR's Receives Regulatory Clearance for SyMRI in the UK
AQ
More news
Financials
Sales 2023 90,8 M 8,34 M 8,34 M
Net income 2023 13,8 M 1,27 M 1,27 M
Net cash 2023 36,9 M 3,39 M 3,39 M
P/E ratio 2023 84,1x
Yield 2023 0,54%
Capitalization 1 095 M 101 M 101 M
EV / Sales 2023 11,7x
EV / Sales 2024 8,64x
Nbr of Employees 31
Free-Float 51,5%
Chart SYNTHETICMR AB (PUBL)
Duration : Period :
SyntheticMR AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 27,90 SEK
Average target price 30,00 SEK
Spread / Average Target 7,53%
EPS Revisions
Managers and Directors
Ulrik Harrysson Chief Executive Officer
Kyle Frye President & Chief Commercial Officer
Johanna NorÚn CFO & Head-Investor Relations
Johan Sedihn Chairman
Markus Malmgren Chief Technology Officer, Head-R&D
Sector and Competitors
1st jan.Capi. (M$)
SYNTHETICMR AB (PUBL)-17.94%107
VEEVA SYSTEMS INC.17.04%30 263
PRO MEDICUS LIMITED14.88%4 421
EVOLENT HEALTH, INC.15.53%3 605
OMNICELL, INC.47.68%3 423
SECTRA AB (PUBL)25.47%3 304
Stock markets for all
100% Free Registration
fermer